Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer.

This is the authors' abstract. We don't add key points for this paper.

This randomized trial demonstrates a survival benefit in anthracycline-refractory ABC. NVB was well tolerated and demonstrated activity superior to ALK in anthracycline-refractory ABC, without compromising QL. Based on activity of single-agent NVB in this difficult-to-treat patient population, investigations of NVB in combination with other anticancer drugs are warranted.